Company / R&D per Share
Rein Therapeutics, Inc. R&D per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.66
FY2025
5-year range
$0.25 / $3.96
FY2021-FY2025
Trend
-19.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has fluctuated over the past 9 years, ranging from $0.25 in FY2021 to $18.11 in FY2017.
Based on SEC 10-K filings.
0.66 in FY2025 with a 5-year CAGR of +0.7%.
Declined from $3.96 to $0.66 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -44.1%
- 5-Year CAGR
- +0.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 19.5% year-over-year.
- Peak r&d per share was recorded in FY2017.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.66 | -19.5% |
| FY2024 | $0.82 | -79.4% |
| FY2023 | $3.96 | +5.3% |
| FY2022 | $3.76 | +1373.3% |
| FY2021 | $0.25 | -59.9% |
| FY2020 | $0.64 | -49.2% |
| FY2019 | $1.25 | +29.3% |
| FY2018 | $0.97 | -94.7% |
| FY2017 | $18.11 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026